
Precipio PRPO
€ 24.39
9.7%
Geschäftsbericht 2025
hinzugefügt 30.03.2026
Precipio DSO 2011-2026 | PRPO
DSO Jährlich Precipio
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21.1 | 20.7 | 28.1 | 33.6 | 32.4 | 52.4 | 67 | 87.9 | 155 | 52.7 | 58.3 | 103 | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 155 | 20.7 | 59.3 |
DSO Vierteljährlich Precipio
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23.2 | 19.9 | 16.4 | - | 18.6 | 20.7 | 29.3 | - | 23.9 | 22.5 | 30.7 | - | 42.9 | 44.1 | 34.5 | - | 20.6 | 20.8 | 37.5 | - | 49 | 61 | 54.3 | - | 66.8 | 55.6 | 80.9 | - | 96.9 | 77.1 | 91 | - | 247 | 256 | 77.5 | - | 77.5 | 55.4 | 94.5 | - | 73 | 54.5 | 44.4 | 34.7 | 146 | 103 | 94.5 | 78 | 73 | 66.4 | 82.9 | 101 | 93.5 | 81.1 | 99.1 | 80.6 | 83.7 | 90.1 | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 256 | 16.4 | 69.3 |
DSO anderer Aktien in der Diagnostik & Forschung
| Name | DSO | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
145 | - | -6.23 % | $ 30.6 M | ||
|
Aspira Women's Health
AWH
|
1.17 K | - | -6.19 % | $ 10.5 M | ||
|
Agilent Technologies
A
|
63.8 | $ 113.88 | -0.84 % | $ 34.6 B | ||
|
Biocept
BIOC
|
112 | - | -13.05 % | $ 7.29 M | ||
|
Castle Biosciences
CSTL
|
49.2 | $ 24.83 | 0.4 % | $ 690 M | ||
|
Danaher Corporation
DHR
|
55.3 | $ 191.01 | -0.56 % | $ 136 B | ||
|
DermTech
DMTK
|
80.6 | - | -11.32 % | $ 2.94 M | ||
|
Enzo Biochem
ENZ
|
50.3 | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
30.8 | - | - | $ 19.8 B | ||
|
Fulgent Genetics
FLGT
|
77.4 | $ 15.91 | -3.11 % | $ 481 M | ||
|
Guardant Health
GH
|
46.1 | $ 93.3 | 4.06 % | $ 11.7 B | ||
|
CareDx, Inc
CDNA
|
51.5 | $ 17.67 | -0.84 % | $ 942 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
90.8 | - | - | $ 562 M | ||
|
DexCom
DXCM
|
87 | $ 63.11 | -0.16 % | $ 24.6 B | ||
|
Akumin
AKU
|
57.4 | - | -17.87 % | $ 25.9 M | ||
|
Heska Corporation
HSKA
|
40.8 | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
101 | - | -20.0 % | $ 1.06 M | ||
|
ICON Public Limited Company
ICLR
|
68.5 | $ 107.16 | -2.24 % | $ 8.84 B | ||
|
Burning Rock Biotech Limited
BNR
|
31.7 | $ 16.09 | -1.29 % | $ 173 M | ||
|
IQVIA Holdings
IQV
|
73.9 | $ 170.62 | -0.01 % | $ 29.3 B | ||
|
Co-Diagnostics
CODX
|
94.7 | $ 4.4 | 101.83 % | $ 5.85 M | ||
|
Accelerate Diagnostics
AXDX
|
291 | - | -61.36 % | $ 2.46 M | ||
|
Global Cord Blood Corporation
CO
|
112 | - | - | $ 399 M | ||
|
Laboratory Corporation of America Holdings
LH
|
52.9 | $ 269.17 | -1.93 % | $ 22.4 B | ||
|
Fluidigm Corporation
FLDM
|
67.2 | - | 1.08 % | $ 308 M | ||
|
Lantheus Holdings
LNTH
|
80.5 | $ 78.08 | 2.89 % | $ 5.27 B | ||
|
Genetic Technologies Limited
GENE
|
11.7 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
122 | - | 0.12 % | $ 80.1 M | ||
|
Medpace Holdings
MEDP
|
50.4 | $ 508.52 | 2.52 % | $ 14.7 B | ||
|
Charles River Laboratories International
CRL
|
65 | $ 169.54 | 0.78 % | $ 8.4 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
98.1 | - | - | $ 10.7 B | ||
|
Motus GI Holdings
MOTS
|
77.2 | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
66.4 | $ 1 270.0 | 0.27 % | $ 26.2 B | ||
|
Myriad Genetics
MYGN
|
52.3 | $ 4.74 | 1.5 % | $ 439 M | ||
|
NeoGenomics
NEO
|
77.7 | $ 8.06 | 0.5 % | $ 1.03 B | ||
|
Neogen Corporation
NEOG
|
66.6 | $ 9.98 | 4.39 % | $ 2.16 B | ||
|
Natera
NTRA
|
81.5 | $ 209.27 | 2.15 % | $ 20.6 B | ||
|
Biodesix
BDSX
|
41.7 | $ 14.53 | -5.4 % | $ 1.88 B | ||
|
OpGen
OPGN
|
4.66 | - | -16.95 % | $ 1.54 M | ||
|
Pacific Biosciences of California
PACB
|
71.8 | $ 1.44 | 1.41 % | $ 432 M | ||
|
PerkinElmer
PKI
|
92.2 | - | -0.91 % | $ 14.7 B | ||
|
Personalis
PSNL
|
55.8 | $ 6.17 | -6.23 % | $ 366 M | ||
|
Quotient Limited
QTNT
|
45.1 | - | -11.32 % | $ 1.1 M | ||
|
Illumina
ILMN
|
61.3 | $ 126.44 | -1.02 % | $ 20.1 B | ||
|
QIAGEN N.V.
QGEN
|
30.8 | - | - | $ 10.6 B | ||
|
Anixa Biosciences
ANIX
|
275 | $ 2.69 | 3.86 % | $ 87.3 K | ||
|
Biomerica
BMRA
|
57.7 | $ 2.16 | -0.46 % | $ 4.96 M | ||
|
BioNano Genomics
BNGO
|
63.7 | $ 1.17 | 1.74 % | $ 6.37 M | ||
|
Interpace Biosciences
IDXG
|
66.9 | $ 2.0 | 1.27 % | $ 8.85 M |